Study Shows Benefit of Multiple Assessments of MRD in Multiple Myeloma
A study affirmed the benefits of a multimodal approach in the assessment of minimal residual disease in multiple myeloma.
Home
Waiting for CAR-T
Choosing the best bridging therapy for a patient, prior to administration of CAR-T, is dependent on the patient’s disease characteristics.
Use of Pathogenic BRCA1/2 Alterations as Pan-Cancer Biomarkers for Therapy Selection May Not be Appropriate
In this study, the degree of homologous recombination deficiency was not predictable across cancer types using BRCA1/2 status.
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
Mutated ATM and unmutated IGHV were identified as potential early drivers of disease in treatment-naive patients with chronic lymphocytic leukemia.
Proposed CMS Rule Change Would Restrict Access to Anticancer Medications
Of the 143 brand name protected class drugs that exist, more than half are antineoplastics.
Surveillance Imaging Not Linked to Better Outcomes in Follicular Lymphoma, Further Evidence Shows
Another study showed that surveillance imaging for patients with follicular lymphoma did not improve survival outcomes after first relapse.
Frailty Predicts Higher In-Hospital Mortality After Radical Cystectomy
Frail patients are more likely than non-frail patients to experience adverse perioperative outcomes after radical cystectomy, a study found.
Risk Factors for CVD More Common in Postmenopausal Women Who Survived Breast Cancer
Researchers compared the development of specific CVD risk factors in postmenopausal women who survived breast cancer and women without history of breast cancer.
Depression at Time of Diagnosis May Worsen Survival in Blood Cancers
Risk for death higher even with depression remission versus never experiencing depression.
RCC Ablation Technique Influences Survival Time
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Want to read more?
Please login or register first to view this content.
Next post in Renal Cell Carcinoma
